Our genome-wide CRISPR knockout screen during imlunestrant treatment showed that known vulnerabilities in HR+ breast cancer, such as genes related to the CDK4/6-RB1 axis and PI3Kinase signaling pathway, remain essential in the presence of imlunestrant treatment. The gene discussed is RB1; the disease is breast cancer.